107 related articles for article (PubMed ID: 8424404)
1. A phase II trial of Didemnin B (NSC #335319) in patients with previously treated epithelial ovarian cancer. A Gynecologic Oncology Group Study.
Malfetano JH; Blessing JA; Jacobs AJ
Am J Clin Oncol; 1993 Feb; 16(1):47-9. PubMed ID: 8424404
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of didemnin B (NSC No. 325319) in advanced and recurrent cervical carcinoma: a Gynecologic Oncology Group study.
Jacobs AJ; Blessing JA; Munoz A
Gynecol Oncol; 1992 Mar; 44(3):268-70. PubMed ID: 1541440
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of didemnin B (NSC #335319) in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study.
Malfetano JH; Blessing JA; Homesley HD; Look KY; McGehee R
Am J Clin Oncol; 1996 Apr; 19(2):184-6. PubMed ID: 8610646
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of didemnin-B in advanced epithelial ovarian cancer. A Southwest Oncology Group study.
Cain JM; Liu PY; Alberts DE; Gallion HH; Laufman L; O'Sullivan J; Weiss G; Bickers JN
Invest New Drugs; 1992 Apr; 10(1):23-4. PubMed ID: 1607250
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of gallium nitrate (NSC #15200) in previously treated ovarian carcinoma. A Gynecologic Oncology Group Study.
Malfetano JH; Blessing JA; Adelson MD
Am J Clin Oncol; 1991 Aug; 14(4):349-51. PubMed ID: 1862766
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase II trial of trimetrexate or didemnin B for the treatment of metastatic or recurrent squamous carcinoma of the uterine cervix: a Southwest Oncology Group trial.
Weiss GR; Liu PY; O'Sullivan J; Alberts DS; Brown TD; Neefe JR; Hutchins LF
Gynecol Oncol; 1992 Jun; 45(3):303-6. PubMed ID: 1535329
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of didemnin B in myeloma. A Cancer and Leukemia Group B (CALGB) study.
Weiss RB; Peterson BL; Allen SL; Browning SM; Duggan DB; Schiffer CA
Invest New Drugs; 1994; 12(1):41-3. PubMed ID: 7960604
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of Didemnin B (NSC 325319) in advanced malignant melanoma: an Eastern Cooperative Oncology Group study (PB687).
Hochster H; Oratz R; Ettinger DS; Borden E
Invest New Drugs; 1998-1999; 16(3):259-63. PubMed ID: 10360606
[TBL] [Abstract][Full Text] [Related]
9. Didemnin B in metastatic malignant melanoma: a phase II trial of the Southwest Oncology Group.
Sondak VK; Kopecky KJ; Liu PY; Fletcher WS; Harvey WH; Laufman LR
Anticancer Drugs; 1994 Apr; 5(2):147-50. PubMed ID: 8049497
[TBL] [Abstract][Full Text] [Related]
10. A Gynecologic Oncology Group phase II study of amonafide (NSC 308847) in epithelial ovarian cancer.
Asbury RF; Blessing JA; Look KY; Clarke-Pearson D; Homesley HD
Am J Clin Oncol; 1993 Dec; 16(6):529-31. PubMed ID: 8256772
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of Didemnin B in central nervous system tumors: a Southwest Oncology Group study.
Taylor SA; Giroux DJ; Jaeckle KA; Panella TJ; Dakhil SR; Schold SC
Invest New Drugs; 1998-1999; 16(4):331-2. PubMed ID: 10426666
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of merbarone (NSC 336628) in the treatment of recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study.
Look KY; Blessing JA; Adelson MD; Morris M; Bookman MA
Am J Clin Oncol; 1996 Feb; 19(1):7-9. PubMed ID: 8554040
[TBL] [Abstract][Full Text] [Related]
13. Phase II clinical trial of didemnin B in patients with recurrent or refractory anaplastic astrocytoma or glioblastoma multiforme (NSC 325319).
Mittelman A; Chun HG; Puccio C; Coombe N; Lansen T; Ahmed T
Invest New Drugs; 1999; 17(2):179-82. PubMed ID: 10638489
[TBL] [Abstract][Full Text] [Related]
14. Phase II trail of didemnin B in previously treated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group (ECOG) Study.
Kucuk O; Young ML; Habermann TM; Wolf BC; Jimeno J; Cassileth PA
Am J Clin Oncol; 2000 Jun; 23(3):273-7. PubMed ID: 10857892
[TBL] [Abstract][Full Text] [Related]
15. Phase II clinical trial of didemnin B in previously treated small cell lung cancer.
Shin DM; Holoye PY; Forman A; Winn R; Perez-Soler R; Dakhil S; Rosenthal J; Raber MN; Hong WK
Invest New Drugs; 1994; 12(3):243-9. PubMed ID: 7896544
[TBL] [Abstract][Full Text] [Related]
16. Phase II evaluation of didemnin B in hormonally refractory metastatic prostate cancer. A Southwest Oncology Group study.
Williamson SK; Wolf MK; Eisenberger MA; O'Rourke M; Brannon W; Crawford ED
Invest New Drugs; 1995; 13(2):167-70. PubMed ID: 8617581
[TBL] [Abstract][Full Text] [Related]
17. Phase II evaluation of didemnin B in advanced adenocarcinoma of the kidney. A Southwest Oncology Group study.
Taylor SA; Goodman P; Crawford ED; Stuckey WJ; Stephens RL; Gaynor ER
Invest New Drugs; 1992 Apr; 10(1):55-6. PubMed ID: 1607254
[TBL] [Abstract][Full Text] [Related]
18. Phase II clinical and pharmacological study of didemnin B in patients with metastatic breast cancer.
Benvenuto JA; Newman RA; Bignami GS; Raybould TJ; Raber MN; Esparza L; Walters RS
Invest New Drugs; 1992 Jul; 10(2):113-7. PubMed ID: 1500265
[TBL] [Abstract][Full Text] [Related]
19. A phase II evaluation of menogaril in cisplatin-refractory advanced ovarian carcinoma. A collaborative trial of the North Central Cancer Treatment Group and the Mayo Clinic.
Long HJ; Laurie JA; Wieand HS; Edmonson JH; Levitt R; Krook JE; Abu-Ghazaleh S
Cancer; 1991 Aug; 68(4):730-2. PubMed ID: 1830238
[TBL] [Abstract][Full Text] [Related]
20. Didemnin B in favourable histology non-Hodgkin's lymphoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group.
Goss G; Muldal A; Lohmann R; Taylor M; Lopez P; Armitage G; Steward WP
Invest New Drugs; 1995; 13(3):257-60. PubMed ID: 8729956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
